Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Towa’s Yoshida Appointed New JGA President, Says Achieving Roadmap Goals Important
May 23, 2013
- EFPIA Japan Chairman Fauchet Prods for Review of 14 Day Prescription Limit
May 21, 2013
- New PhRMA Chairman Tells Prime Minister Abe, Pro-Innovation Policies Key to Maintaining Japanese Healthcare System
May 16, 2013
- Kyokai Kenpo Launches Trial Notification Service on Copayment Differences between Original, Generic Anti-Allergy Drugs
May 8, 2013
- Vital-Net Pres. Suzuki Tipped to Be Next President of JPWA; Number of VPs to Be Increased to 5
May 2, 2013
- Itsuro Yoshida of Towa Pharmaceutical Expected to Take Over as Next President of JGA
April 25, 2013
- “Both Sides Need to Work Harder” to Reach Agreements on Delivery Prices: Mr Nakamura of NPhA
April 23, 2013
- JPMA to Call on Its Member Companies to Ask Lecturers at Seminars Sponsored by Them for Their Permission to Disclose COI-Related Information
April 22, 2013
- JPMA Reinstates MSD K.K. as Member After 22-Month Suspension
April 22, 2013
- Tug-of-War over “Conflicts of Interest” (1): Drug Makers, Doctors Remain Divided
April 18, 2013
- APAC to Draft Roadmap for Early Drug Application and Approval in Asia
April 16, 2013
- JPMA Eyes Joint Communications Campaigns for Transparency Guidelines with JMA, JAMS
April 12, 2013
- Pharma Officials Puzzled at Fuzzy Communications Provision in JPMA Code of Practice
April 1, 2013
- Keizai Doyukai Urges Government to Switch All Long-Listed Products to Generics to Cut Social Security Costs
March 29, 2013
- Survey by Japan Hospital Association Finds Big Increase in Accounts Receivable per Hospital in 2012
March 27, 2013
- FPMAJ to Set Up International Affairs Committee and Self-Medication Task Force
March 25, 2013
- JPMA Suspends Activities of Vice President Hasegawa for Six Months and Membership of Nihon Pharmaceutical
March 22, 2013
- JPMA Officially Decides on One-Year Postponement of Individual Payment Disclosures under Transparency Guidelines
March 22, 2013
- JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
March 22, 2013
- EFPIA Simulation: New Drug Market Up Mere 0.4 Trillion Yen by 2022 Even with Premium
March 19, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…